Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Stem Cells in Drug Discovery Tox & Organoids 2019

Terry Riss's Biography



Terry Riss, Global Strategic Marketing Manager Cell Health, Promega Corporation

Dr. Riss received a PhD in Cell Biology from the University of Illinois in 1978 in the field of mammary gland biology. He did postdoctoral work at the University of Texas Medical School developing bioassays to study breast cancer. Dr. Riss moved to the Biotechnology division of Schering Plough in 1988 to develop interleukin/cytokine bioassays to support IND filings. Dr. Terry Riss started the Cell Biology program at Promega Corporation in 1990 where he has held several R&D and Project Management positions. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and lead efforts to promote multiplexing of cell-based assays to determine the mechanism of cell death. Dr. Riss now serves as Global Strategic Manager, Cell Health involved in outreach educational training activities. Dr. Riss serves as a co-editor of the NIH Assay Guidance Manual.

Terry Riss Image

Chairman’s Opening Remarks: Designing and Validating Fit-for-Purpose Assays to Interrogate 3D Culture Models

Monday, 14 October 2019 at 13:30

Add to Calendar ▼2019-10-14 13:30:002019-10-14 14:30:00Europe/LondonChairman’s Opening Remarks: Designing and Validating Fit-for-Purpose Assays to Interrogate 3D Culture ModelsStem Cells in Drug Discovery Tox and Organoids 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

There continues to be a rapid expansion in the use of 3D cell culture model systems because they more closely represent the in vivo situation compared to culturing cells as a monolayer attached to plastic. There are many approaches classified as 3D culture models ranging from individual scaffold-free spheroids to multiple organoids designed to represent a human-on-a-chip. Researchers soon become aware the spectrum of 3D models have vastly different requirements and there is no “one size fits all” approach. Selecting a 3D culture model that is “fit for purpose” involves several decisions and often results in a compromise considering sample throughput, complexity, physiological relevance, cost and limitations in the assay technologies. I will describe an overview of factors to consider when designing an appropriate 3D culture model and stress the importance of considering limitations of assay methods to interrogate relatively large 3D structures. I encourage the other speakers in this session to address both the advantages and limitations of the model systems they present.


Add to Calendar ▼2019-10-14 00:00:002019-10-15 00:00:00Europe/LondonStem Cells in Drug Discovery Tox and Organoids 2019Stem Cells in Drug Discovery Tox and Organoids 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com